Enough stock of Hydroxychloroquine to meet the demand, says Centre

On Monday, the Union government reiterated that Indian Pharma industry has sufficient stocks of essential medicines particularly HCQ to meet both domestic demand and export obligations.

The production & transportation is being coordinated throughout the nation by the Department of Pharmaceuticals. This position emerged after a video conference meeting held under the chairmanship of Dr P D Vaghela, Secretary of the Department of Pharmaceuticals.


Effectiveness of HCQ:

The HCQ drug is proven to treat malaria, lupus, and rheumatoid arthritis.

However, the drug has been touted as a possible cure for COVID-19 by the US President Donald Trump as he termed the anti-malarial drug as a “game-changer”.

Notably, two large trials are currently in progress on the effectiveness of Hydroxychloroquine and even chloroquine.

HCQ Production in India:

India is one of the world’s leading producers of hydroxychloroquine (HCQ), an anti-malarial drug. According to industry experts, India has a total capacity to produce about 300 – 350 million tablets of HCQ per month.

According to some reports, India exports around $50 million of the medicine annually. Zydus Cadila & Ipca Laboratories are the biggest manufacturers of the “game-changer” drug.

To meet the ever-rising demand, Indian pharma companies have planned to raise HCQ’s monthly production four times by the end of this month and five to six times by next month.